Press release summary
Scitara has outlined a new strategy that expands its focus from laboratory connectivity into what it calls lab intelligence. The company plans to continue developing integrations and data infrastructure while adding laboratory-specific artificial intelligence applications and agentic orchestration for multistep scientific workflows.
Scitara said its DLX platform connects instruments, applications, and data across development, manufacturing, and quality-control environments at 10 of the 25 largest global biopharmaceutical companies. Its planned work includes preparing manufacturing and QC data for AI models, supporting next-generation informatics systems, and developing an intelligence layer for more autonomous laboratories. The company also named former AWS and TetraScience executive Mike Tarselli as chief strategy officer.
Why it matters for laboratories
Laboratories often cannot apply AI reliably until instrument data, identifiers, permissions, and provenance are governed across systems. Scitara’s strategy places that integration foundation beneath emerging agentic workflows, an architecture that may appeal to regulated organizations seeking automation without disconnecting it from existing systems of record. The announcement is a strategic roadmap rather than a product-validation report. Buyers should ask which capabilities are available now, which remain planned, how human approval is enforced, and what audit evidence is retained when software coordinates laboratory actions.
Original source: Scitara release distributed through Business Wire, Sept. 21, 2026.
